Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchitis, Chronic | 20 | 2024 | 82 | 7.970 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 66 | 2024 | 3202 | 6.180 |
Why?
|
| Pulmonary Emphysema | 17 | 2023 | 685 | 2.140 |
Why?
|
| Goblet Cells | 5 | 2020 | 298 | 1.810 |
Why?
|
| Forced Expiratory Volume | 29 | 2023 | 1812 | 1.600 |
Why?
|
| Bronchodilator Agents | 9 | 2022 | 512 | 1.340 |
Why?
|
| Smoking | 28 | 2024 | 9046 | 1.310 |
Why?
|
| Spirometry | 21 | 2023 | 928 | 0.930 |
Why?
|
| Expectorants | 3 | 2019 | 22 | 0.880 |
Why?
|
| Mucus | 6 | 2023 | 341 | 0.870 |
Why?
|
| Lung | 19 | 2023 | 9973 | 0.800 |
Why?
|
| Vital Capacity | 12 | 2023 | 970 | 0.730 |
Why?
|
| Bronchitis | 1 | 2021 | 196 | 0.710 |
Why?
|
| Respiratory Function Tests | 13 | 2022 | 1681 | 0.680 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2018 | 344 | 0.650 |
Why?
|
| Sputum | 3 | 2021 | 506 | 0.610 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2019 | 308 | 0.590 |
Why?
|
| Total Lung Capacity | 2 | 2020 | 149 | 0.570 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 224 | 0.570 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 135 | 0.570 |
Why?
|
| Chemokines | 2 | 2017 | 960 | 0.480 |
Why?
|
| Disease Progression | 13 | 2023 | 13484 | 0.460 |
Why?
|
| Pneumonectomy | 3 | 2012 | 1110 | 0.450 |
Why?
|
| Mucociliary Clearance | 1 | 2014 | 80 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2023 | 20551 | 0.420 |
Why?
|
| Quality of Life | 17 | 2024 | 13338 | 0.410 |
Why?
|
| Nutrition Surveys | 2 | 2019 | 1726 | 0.400 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2018 | 410 | 0.380 |
Why?
|
| Occupational Exposure | 2 | 2020 | 1811 | 0.350 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 1874 | 0.340 |
Why?
|
| Residence Characteristics | 1 | 2020 | 2087 | 0.340 |
Why?
|
| Bronchioles | 1 | 2008 | 30 | 0.320 |
Why?
|
| Aged | 46 | 2024 | 168840 | 0.320 |
Why?
|
| Adiponectin | 1 | 2014 | 1113 | 0.320 |
Why?
|
| Middle Aged | 53 | 2024 | 220382 | 0.310 |
Why?
|
| Airway Remodeling | 4 | 2021 | 133 | 0.300 |
Why?
|
| Receptors, CXCR3 | 1 | 2009 | 238 | 0.300 |
Why?
|
| Respiratory Mucosa | 2 | 2008 | 439 | 0.300 |
Why?
|
| Severity of Illness Index | 15 | 2022 | 15820 | 0.290 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 445 | 0.290 |
Why?
|
| Emphysema | 2 | 2022 | 238 | 0.290 |
Why?
|
| Mucins | 4 | 2015 | 568 | 0.280 |
Why?
|
| Leptin | 1 | 2014 | 1593 | 0.270 |
Why?
|
| Airway Obstruction | 2 | 2023 | 661 | 0.270 |
Why?
|
| Male | 57 | 2024 | 360035 | 0.260 |
Why?
|
| Female | 61 | 2024 | 391875 | 0.260 |
Why?
|
| Humans | 80 | 2024 | 760437 | 0.250 |
Why?
|
| Pulmonary Alveoli | 1 | 2008 | 650 | 0.250 |
Why?
|
| Hyperplasia | 2 | 2020 | 1153 | 0.240 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 2723 | 0.240 |
Why?
|
| Endopeptidases | 1 | 2008 | 772 | 0.230 |
Why?
|
| Respiratory System | 2 | 2019 | 563 | 0.230 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2004 | 170 | 0.210 |
Why?
|
| Administration, Inhalation | 4 | 2022 | 1156 | 0.210 |
Why?
|
| Bronchi | 2 | 2019 | 845 | 0.210 |
Why?
|
| Body Mass Index | 5 | 2022 | 12932 | 0.200 |
Why?
|
| Smoking Cessation | 4 | 2018 | 2053 | 0.200 |
Why?
|
| Weight Gain | 1 | 2012 | 2346 | 0.200 |
Why?
|
| Asthma | 7 | 2022 | 6195 | 0.200 |
Why?
|
| Depression | 5 | 2022 | 8104 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7380 | 0.180 |
Why?
|
| Fractals | 1 | 2021 | 128 | 0.170 |
Why?
|
| South America | 1 | 2020 | 179 | 0.170 |
Why?
|
| Case-Control Studies | 8 | 2019 | 22097 | 0.170 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 12054 | 0.170 |
Why?
|
| Tomography | 1 | 2021 | 411 | 0.160 |
Why?
|
| Reference Values | 2 | 2019 | 4921 | 0.160 |
Why?
|
| Latin America | 1 | 2020 | 410 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2021 | 367 | 0.150 |
Why?
|
| Logistic Models | 5 | 2020 | 13240 | 0.150 |
Why?
|
| Risk Factors | 16 | 2023 | 74055 | 0.150 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 1780 | 0.150 |
Why?
|
| Dyspnea | 4 | 2022 | 1344 | 0.150 |
Why?
|
| Hospitalization | 3 | 2014 | 10698 | 0.140 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 397 | 0.130 |
Why?
|
| Exercise Tolerance | 4 | 2015 | 835 | 0.130 |
Why?
|
| Comorbidity | 5 | 2022 | 10494 | 0.130 |
Why?
|
| Chemokine CCL7 | 1 | 2015 | 30 | 0.130 |
Why?
|
| Chemokine CCL22 | 1 | 2015 | 27 | 0.130 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 84 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 126 | 0.130 |
Why?
|
| Interleukin-9 | 1 | 2015 | 61 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 632 | 0.120 |
Why?
|
| Macrophage Activation | 1 | 2018 | 552 | 0.120 |
Why?
|
| Cough | 2 | 2016 | 594 | 0.120 |
Why?
|
| Epidermal Growth Factor | 2 | 2015 | 700 | 0.120 |
Why?
|
| Bronchoscopy | 2 | 2019 | 909 | 0.120 |
Why?
|
| Cohort Studies | 11 | 2023 | 41366 | 0.120 |
Why?
|
| Linear Models | 4 | 2018 | 5865 | 0.120 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 111 | 0.110 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 3183 | 0.110 |
Why?
|
| Albuterol | 1 | 2014 | 213 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 543 | 0.110 |
Why?
|
| Bronchography | 1 | 2013 | 75 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 604 | 0.110 |
Why?
|
| Prospective Studies | 9 | 2022 | 54339 | 0.100 |
Why?
|
| Xanthines | 1 | 2012 | 120 | 0.100 |
Why?
|
| Glucocorticoids | 2 | 2012 | 2163 | 0.100 |
Why?
|
| United States | 14 | 2024 | 72202 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2015 | 696 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 2008 | 926 | 0.100 |
Why?
|
| Apoptosis | 1 | 2008 | 9468 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2012 | 168 | 0.100 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2012 | 213 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 2015 | 1250 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 2015 | 1130 | 0.100 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 1301 | 0.100 |
Why?
|
| Aged, 80 and over | 9 | 2023 | 58859 | 0.100 |
Why?
|
| Cytokines | 2 | 2017 | 7377 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2022 | 23953 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2007 | 3421 | 0.090 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2011 | 144 | 0.090 |
Why?
|
| Republic of Korea | 2 | 2024 | 571 | 0.090 |
Why?
|
| Survival Rate | 3 | 2018 | 12698 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2011 | 93 | 0.090 |
Why?
|
| Anxiety | 3 | 2022 | 4558 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 1177 | 0.090 |
Why?
|
| Cell Count | 1 | 2015 | 1834 | 0.090 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 2897 | 0.080 |
Why?
|
| Hydroxyurea | 1 | 2011 | 282 | 0.080 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 26063 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2015 | 907 | 0.080 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 135 | 0.080 |
Why?
|
| Respiratory Tract Diseases | 1 | 2014 | 748 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 39078 | 0.080 |
Why?
|
| Monocytes | 1 | 2018 | 2572 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2019 | 64591 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2014 | 2612 | 0.080 |
Why?
|
| Metaplasia | 1 | 2008 | 321 | 0.070 |
Why?
|
| Chemokine CXCL10 | 1 | 2009 | 316 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2019 | 1953 | 0.070 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 162 | 0.070 |
Why?
|
| Aircraft | 1 | 2008 | 125 | 0.070 |
Why?
|
| Airway Resistance | 1 | 2008 | 406 | 0.070 |
Why?
|
| Adult | 10 | 2020 | 220781 | 0.070 |
Why?
|
| Polysomnography | 2 | 2016 | 1839 | 0.070 |
Why?
|
| Radiography | 2 | 2014 | 6963 | 0.070 |
Why?
|
| Hypertrophy | 1 | 2008 | 559 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 2166 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2012 | 1471 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 29551 | 0.060 |
Why?
|
| Health Status | 2 | 2022 | 4071 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2015 | 3209 | 0.060 |
Why?
|
| Medical Records | 1 | 2011 | 1407 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 7424 | 0.060 |
Why?
|
| Antioxidants | 1 | 2012 | 1670 | 0.060 |
Why?
|
| Time Factors | 5 | 2018 | 39947 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 3486 | 0.060 |
Why?
|
| Proportional Hazards Models | 4 | 2022 | 12429 | 0.060 |
Why?
|
| Pulmonary Fibrosis | 1 | 2008 | 505 | 0.060 |
Why?
|
| Prevalence | 4 | 2024 | 15698 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2014 | 9639 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2004 | 348 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13312 | 0.060 |
Why?
|
| Macrophages | 1 | 2018 | 5764 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 1870 | 0.050 |
Why?
|
| Hypoxanthines | 1 | 2021 | 35 | 0.050 |
Why?
|
| Body Weight | 1 | 2012 | 4614 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2023 | 14565 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2021 | 174 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 15257 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2023 | 5236 | 0.050 |
Why?
|
| Sex Factors | 1 | 2014 | 10538 | 0.040 |
Why?
|
| Phenotype | 3 | 2014 | 16585 | 0.040 |
Why?
|
| Chlorobenzenes | 1 | 2019 | 28 | 0.040 |
Why?
|
| Benzyl Alcohols | 1 | 2019 | 30 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2019 | 48 | 0.040 |
Why?
|
| Uteroglobin | 1 | 2019 | 56 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 128 | 0.040 |
Why?
|
| Inflammation | 2 | 2008 | 10746 | 0.040 |
Why?
|
| Rheology | 1 | 2019 | 348 | 0.040 |
Why?
|
| Eosinophils | 1 | 2022 | 947 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2008 | 4167 | 0.040 |
Why?
|
| Diffusion | 1 | 2019 | 814 | 0.040 |
Why?
|
| Androstadienes | 1 | 2019 | 348 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 17854 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2017 | 397 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2018 | 486 | 0.030 |
Why?
|
| Walking | 2 | 2014 | 1199 | 0.030 |
Why?
|
| Incidence | 3 | 2022 | 21322 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 2018 | 412 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2019 | 889 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 4748 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2016 | 6340 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2023 | 80430 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11070 | 0.030 |
Why?
|
| Systems Biology | 1 | 2018 | 481 | 0.030 |
Why?
|
| Obesity | 1 | 2016 | 12918 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2326 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2016 | 364 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 410 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 59068 | 0.030 |
Why?
|
| Norway | 1 | 2014 | 497 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2012 | 24 | 0.030 |
Why?
|
| Chest Pain | 1 | 2019 | 1090 | 0.020 |
Why?
|
| Theophylline | 1 | 2012 | 131 | 0.020 |
Why?
|
| Organ Size | 1 | 2016 | 2252 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 88196 | 0.020 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 471 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 10188 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2012 | 138 | 0.020 |
Why?
|
| Leukotriene E4 | 1 | 2011 | 75 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 2717 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2357 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2011 | 280 | 0.020 |
Why?
|
| Exercise Test | 1 | 2017 | 2127 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 6297 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 12969 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 1750 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2018 | 5865 | 0.020 |
Why?
|
| Age of Onset | 1 | 2014 | 3302 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 3822 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 12653 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 1564 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6765 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 15867 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10075 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2011 | 12320 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2014 | 2626 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 2642 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 12976 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2012 | 4010 | 0.010 |
Why?
|
| Acute Disease | 1 | 2014 | 7230 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 4849 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 7996 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2012 | 1157 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11526 | 0.010 |
Why?
|
| Oxygen | 1 | 2012 | 4222 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 20078 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 6413 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 168253 | 0.010 |
Why?
|
| Child | 1 | 2014 | 80086 | 0.000 |
Why?
|
Concepts
(232)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_